Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4993377 | 0.89 | KMT2A (0.43) | CNR1AKR1C3AKR1C1TP53MAPT | |
| SCHEMBL4991959 | 0.87 | CD4 (0.38) | CNR1AKR1C3MAPT | |
| SCHEMBL4992564 | 0.86 | MEN1 (0.47) | AKR1C3AKR1C1TP53MAPTGAA | |
| SCHEMBL4988448 | 0.85 | MEN1 (0.45) | AKR1C3AKR1C1GAA | |
| SCHEMBL4988642 | 0.85 | MAPT (0.43) | AKR1C3AKR1C1TP53MAPTAKR1C2 | |
| SCHEMBL5142384 | 0.84 | CNR2 (0.32) | — | |
| SCHEMBL4986058 | 0.83 | USP2 (0.46) | CNR1MAPTGAA | |
| SCHEMBL4986174 | 0.83 | PKM (0.46) | AKR1C3AKR1C1GAA | |
| SCHEMBL4992334 | 0.83 | CNR1 (0.41) | CNR1AKR1C3AKR1C1GAAAKR1C2 | |
| SCHEMBL4988327 | 0.83 | GBA1 (0.48) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | CNR1 49/4885TMEM97 1347/4885SIGMAR1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.